Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 18/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13834173 | 1.00 | LRRK2 (0.66) | LRRK2GAAALOX15TSHRHSD17B10 | |
| SCHEMBL13834153 | 1.00 | LRRK2 (0.66) | LRRK2GAAALOX15TSHRHSD17B10 | |
| SCHEMBL13834167 | 0.95 | LRRK2 (0.74) | LRRK2GAATSHRHSD17B10 | |
| SCHEMBL883324 | 0.95 | LRRK2 (0.74) | LRRK2GAATSHRHSD17B10 | |
| SCHEMBL13834382 | 0.95 | LRRK2 (0.74) | LRRK2GAATSHRHSD17B10 | |
| SCHEMBL3768589 | 0.91 | LRRK2 (0.57) | LRRK2GAATSHRHSD17B10 | |
| SCHEMBL16857686 | 0.91 | LRRK2 (0.57) | LRRK2GAATSHRHSD17B10 | |
| SCHEMBL883325 | 0.90 | LRRK2 (0.60) | LRRK2GAAALOX15TSHRHSD17B10 | |
| SCHEMBL19566703 | 0.87 | LRRK2 (0.62) | LRRK2GAATSHRHSD17B10 | |
| SCHEMBL3766993 | 0.87 | LRRK2 (0.62) | LRRK2GAATSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569281-B2 | Compounds and their administration for treating a neurodegenerative disease as well as a method for identifying a compound capable of inhibiting a kinase, such as LRRK | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2013-10-29 | — | — | US | disclosed |
| US-20120295883-A1 | COMPOUNDS | GENENTECH, INC. (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120295883-A1 | COMPOUNDS | GENENTECH, INC. (US) | 2012-11-22 | — | — | US | disclosed |
| WO-2012038743-A1 | PYRAZOLOPYRIDINES AS INHIBITORS OF THE KINASE LRRK2 | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295883-A1 | COMPOUNDS | ABCC5, PRNP, PC | LRRK2 1512/4885GAA 342/4885ALOX15 2937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.